Julphar Delivered consistent sales growth supported by a stable and resilient profit in YTD September

Julphar posts solid growth and key advancements During Q3, recording net revenue of mAED 249.7, a 5.0% increase lifted YTD Sep net revenue to mAED 796.1, reflecting a 5.8% growth and boosted EBITDA by mAED 28.2 in YTD, rising from mAED 80.5 to mAED 108.7.

13^th November 2025, Ras Al Khaimah, UAE: Gulf Pharmaceutical Industries (Julphar), a prominent pharmaceutical leader in the MENA region, released its Q3 and YTD September financial results, reporting consistent top-line growth and profit acceleration outpacing sales growth.

The company’s focus on cost efficiencies and operational discipline resulted in enhanced profitability from continuing operations. Gross profit rose to mAED 351.1 at a 44.0% margin (+11.9%), while EBITDA reached mAED 108.7, with margin expansion to 14.0% from 11.0% (+35.0%). Net income showed a notable turnaround, increasing from mAED –9.9 to mAED 36.7 compared to last year.

During the period ended 30 September, the Company accepted a binding offer from Al Batha Healthcare Group L.L.C. to acquire selected retail and distribution assets, including the Health First Pharmacy chain in the UAE and the Scientific Pharmacy and distribution operations in Oman. The transaction is pending final regulatory approvals, customary closing conditions, and execution of definitive agreements.

In addition, Julphar expanded its market footprint with 11 new product launches and 23 regulatory approvals, further strengthening commercial execution and broadening its portfolio. The Company also advanced high-potential pipeline assets and enhanced its R&D capabilities, supporting its strategic agenda and long-term growth ambitions.

Sheikh Saqer Bin Humaid Al Qasimi, Chairman of the Board, Julphar, said: “These results reflect the strength of Julphar’s performance and its continued achievement of sustainable growth. We take pride in the efforts of our teams, whose contributions have enhanced operational efficiency and strengthened the company’s position as a trusted partner in supporting the pharmaceutical sector. We will continue our commitment to innovation and development to achieve further progress in the next stage”.

Basel Ziyadeh, Chief Executive Officer, Julphar, added: “We continue to invest with purpose, reinforce our capital strength, and create sustainable value for our shareholders. By empowering our teams, enhancing our capabilities, and driving transformation, we are shaping a stronger, more agile Julphar”.

-Ends-